STAT

Leading scientists, backed by NIH, call for a global moratorium on creating ‘CRISPR babies’

Eighteen scientists from seven countries have called for “a global moratorium on all clinical uses of human germline editing” for at least five years.
Chinese scientist He Jiankui arrives to speak at the Second International Summit on Human Genome Editing in Hong Kong in November 2018.

The Chinese scientist who created “CRISPR babies,” He Jiankui, sincerely believed that the research violated neither his country’s laws nor the guidelines of the international scientific community, according to his friends and colleagues. He didn’t exactly keep his experiment secret: He told at least four U.S. scientists that he was considering establishing pregnancies with genome-edited IVF embryos, enlisted a U.S. scientist to work at his Shenzhen lab, teamed with a Chinese hospital and IVF clinic, and proudly announced the birth of “Nana” and “Lulu” on YouTube in November.

Though researchers forcefully condemned He’s work as unethical and a breach of a scientific red line — and while the Chinese government has since accused him of breaking their laws — He clearly hadn’t gotten the memo.

Now, in an effort to prevent another He, 18 scientists from seven countries have called for “a global moratorium on all clinical uses of human

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks